Avantect changes how and when pancreatic cancer is detected

Avantect changes how and when pancreatic cancer is detected

Pancreatic cancer is a devastating disease, most frequently diagnosed too late.1 The Avantect Pancreatic Cancer Test is a simple cell-free DNA-based blood test designed to help make earlier diagnosis possible,2,3 and to offer an improved chance for successful treatment and longer survival.

Prioritizing high-risk patients

Pancreatic cancer is called a “silent killer” because it often develops without symptoms.4 It is paramount to identify the patient populations who are at high risk, when early detection might make all the difference.3,4

Explore Avantect

The Avantect test is a cell-free DNA (cfDNA)-based blood test for patients at high risk for pancreatic cancer. It combines the most advanced epigenomic and genomic science as well as machine learning to detect the presence or absence of an abnormal signal in the blood—providing guidance for a clear plan of action.

Getting started

It’s easy to incorporate the Avantect test into clinical management protocols for high-risk patients, including routine checkups or blood work. Here is everything you need to know to order this important test.

Stay up to date with Avantect

Complete this form to receive the latest news about the Avantect test.

Contact Customer Success

If you have any questions please call us at +1 833-258-7827.

    Required fields are marked with an *

    Important information

    The Avantect Pancreatic Cancer Test is an early detection test. The test does not establish a diagnosis of pancreatic cancer, and results should be considered in the context of other clinical criteria. Definitive diagnosis of pancreatic cancer usually requires a series of imaging scans, blood tests, and a biopsy. Not all pancreatic cancers will be detected. Some patients with pancreatic cancer may have a “Signal not detected” result. Some patients without pancreatic cancer may have a “Signal detected” result. False-negative and false-positive results are possible. A “Signal not detected” result does not guarantee that no pancreatic cancer is present. In some cases, no result is obtained. While this is very uncommon, it may be caused by shipping delays or when there is not enough cell-free DNA for the test in the patient’s blood. If this happens, we generally ask for a repeat blood sample for testing at no extra cost.

    The test was developed in the ClearNote Health CLIA-certified (CLIA# 05D2249973) and CAP-accredited (CAP# 9219174) laboratory and has not been cleared or approved by the US Food and Drug Administration (FDA).

    References and notes

    1. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: pancreatic cancer. (2012-2018 data). Available at: https://seer.cancer.gov/statfacts/html/pancreas.html. Accessed October 27, 2022.
    2. Bergamaschi A, Haan D, Collins M, et al. Validation of an early-stage pancreatic cancer classification model using 5-hydroxymethylation profiles in plasma-derived cell-free DNA. Poster presented at: American Association for Cancer Research (AACR) Special Conference: Pancreatic Cancer; September 13-16, 2022; Boston, Massachusetts.
    3. Guler GD, Ning Y, Ku CJ, et al. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA. Nat Commun. 2020;11:5270.
    4. Chari ST. Detecting early pancreatic cancer—problems and prospects. Semin Oncol. 2007;34(4):284-294.